Evidence map›Paper›PMID 40163891›Full record

ArticleBlood2025

Hallmarks of T-cell exhaustion and antigen experience are absent in multiple myeloma from diagnosis to maintenance therapy.

Carolyn Shasha, David R Glass, Ernest Moelhman, Laura Islas, Yuan Tian, Tony Chour, Guoyue Xu, Gregory L Szeto, Tao Peng, Xiaoling Song and 7 more

Abstract read
In one paragraph

Article in Blood, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Identification of exhausted CD8Translational cancer research · 2026
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Terminally exhausted CD8Frontiers in immunology · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Carolyn ShashaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0002-3021-9383
David R GlassVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0001-9924-167X
Ernest MoelhmanVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0009-0006-7664-8091
Laura IslasVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0003-1465-3718
Yuan TianVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0001-6073-8582
Tony ChourVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0003-3273-5549
Guoyue XuVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0002-7699-8837
Gregory L SzetoAllen Institute for Immunology, Seattle, WA.ORCID 0000-0001-7604-1333
Tao PengAllen Institute for Immunology, Seattle, WA.ORCID 0000-0003-0550-9183
Xiaoling SongImmunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0001-5969-4025
Michelle WurscherVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0009-0004-8862-5255
Andrew J CowanClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0002-1880-7094
Thomas F BumolAllen Institute for Immunology, Seattle, WA.ORCID 0000-0003-4319-1006
Troy R TorgersonAllen Institute for Immunology, Seattle, WA.ORCID 0000-0003-3489-5036
Philip D GreenbergImmunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0003-3812-647X
Damian J GreenTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0003-0477-1446
Evan W NewellVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0002-2889-243X

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
VIRUS-MEDIATED MYELOSUPPRESSIONP01CA018029 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STEPHANIE J LEE · 1985 to 2026
$128.4M
The roles of EBV-specific T cells in response to checkpoint blockade immunotherapy of EBV-driven nasopharyngeal carcinomaR01CA264646 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI NEWELL, EVAN · 2021 to 2025
$3.0M
NCI NIH HHS P01 CA018029NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA264646
6 · The paper itself

Abstract

abstractDysregulation of the bone marrow (BM) niche in multiple myeloma (MM) alters the composition and state of resident immune cells, potentially impeding antitumor immunity. One common mechanism of immune inhibition in solid tumors is the induction of exhaustion in tumor-specific T cells. However, the extent of T-cell exhaustion is not well characterized in MM. As the specific mechanisms of immune evasion are critical for devising effective therapeutic strategies, we deeply profiled the CD8+ T-cell compartment of patients with newly diagnosed MM (NDMM) for evidence of T-cell activation and exhaustion. We applied single-cell multiomic sequencing and mass cytometry to longitudinal BM and peripheral blood (PB) samples taken from time points spanning from diagnosis to induction therapy, autologous stem cell transplant, and maintenance therapy. We identified an exhausted-like population that lacked several canonical exhaustion markers, was not significantly enriched in patients with NDMM, and consisted of small, nonpersistent clonotypes. We also observed an activated population with increased frequency in the PB of patients with NDMM exhibiting phenotypic and clonal features consistent with homeostatic, cytokine-driven activation. As an orthogonal measurement of T-cell exhaustion, we performed intracellular cytokine staining and found that patients with NDMM lacked functionally exhausted T cells. In summary, there was no evidence of "tumor-experienced" T cells displaying hallmarks of terminal exhaustion and/or antigen-driven activation/expansion in patients with NDMM at any time point.

Indexed as

Antigens, NeoplasmCD8-Positive T-LymphocytesMultiple MyelomaAgedFemaleHumansLymphocyte ActivationMaleMiddle AgedT-Cell ExhaustionAntigens, Neoplasm

Identifiers

PMID40163891
PMCPMC12782984

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.